<p>温和的股價反應表明，<strong>碧迪醫療</strong>（NYSE:BDX）強勁的收益並沒有帶來任何驚喜。我們的分析表明，投資者可能錯過了一些有前景的細節。</p>
<p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行工作。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/103678-earnings-and-revenue-history-1-dark-2/1779215758002?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/103678-earnings-and-revenue-history-1-dark-2/1779215758002"/></p>
<p>NYSE:BDX 收益和收入歷史 2026 年 5 月 19 日</p>
<h2>非常規項目如何影響利潤？</h2>
<p>重要的是，我們的數據表明，碧迪醫療的利潤因非常規項目在過去一年中減少了 13 億美元。看到非常規項目導致公司利潤下降並不理想，但從積極的一面看，情況可能會比預期更快改善。當我們分析全球絕大多數上市公司時，我們發現顯著的非常規項目通常不會重複。這並不令人驚訝，因為這些項目被視為非常規。如果碧迪醫療不再出現這些非常規費用，那麼在其他條件相同的情況下，我們預計其利潤在未來一年將會增加。</p>
<p>這可能會讓你想知道分析師對未來盈利能力的預測。幸運的是，你可以點擊這裏查看基於他們估計的未來盈利能力的互動圖表。</p>
<h2>我們對碧迪醫療利潤表現的看法</h2>
<p>非常規項目（費用）在過去一年中削弱了碧迪醫療的收益，但我們可能會在明年看到改善。基於這一觀察，我們認為碧迪醫療的法定利潤實際上低估了其盈利潛力！此外，其每股收益在過去三年中以每年 5.7% 的速度增長。當然，我們在分析其收益時僅僅是觸及了表面；還可以考慮利潤率、預測增長和投資回報等其他因素。如果你想更深入地瞭解碧迪醫療，你還需要關注它目前面臨的風險。在投資風險方面，<strong>我們已經識別出碧迪醫療的兩個警示信號</strong>，理解這些信號應該是你投資過程的一部分。</p>
<p>今天我們聚焦於一個單一的數據點，以更好地理解碧迪醫療的利潤性質。但如果你能夠專注於細節，總會有更多的發現。有些人認為高股本回報率是優質企業的良好標誌。雖然這可能需要你進行一些研究，但你可能會發現這份 <strong>免費</strong> 的高股本回報率公司集合，或者這份擁有顯著內部持股的股票名單對你有幫助。</p>
<h3>估值是複雜的，但我們在這裏為你簡化。</h3>
<p>通過我們的詳細分析，發現碧迪醫療是否可能被低估或高估，分析內容包括 <strong>公允價值估計、潛在風險、股息、內部交易及其財務狀況。</strong></p>
<p>獲取免費分析</p>

碧迪醫療

美國醫藥設備 ETF - iShares

標普健康醫療設備 ETF - SPDR

<p>貝克頓·迪金森（NYSE:BDX）強勁的收益並未令投資者感到意外，導致股價反應平淡。去年，異常支出使利潤減少了 13 億美元，但分析師表示這些支出可能不會再次出現，暗示未來可能會有利潤增長。該公司的每股收益在過去三年中以每年 5.7% 的速度增長，儘管已識別出兩個投資風險。建議進一步分析以評估貝克頓·迪金森的估值和財務狀況</p>

<p>The subdued stock price reaction suggests that <strong>Becton, Dickinson and Company's</strong> (NYSE:BDX) strong earnings didn't offer any surprises. Our analysis suggests that investors might be missing some promising details.</p>
<div class="lb-trans"><p>温和的股價反應表明，<strong>碧迪醫療</strong>（NYSE:BDX）強勁的收益並沒有帶來任何驚喜。我們的分析表明，投資者可能錯過了一些有前景的細節。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行工作。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/103678-earnings-and-revenue-history-1-dark-2/1779215758002" alt="" original-src="https://images.simplywall.st/asset/chart/103678-earnings-and-revenue-history-1-dark-2/1779215758002"/></p>
<p>NYSE:BDX Earnings and Revenue History May 19th 2026</p>
<div class="lb-trans"><p>NYSE:BDX 收益和收入歷史 2026 年 5 月 19 日</p>
</div><h2>How Do Unusual Items Influence Profit?</h2>
<div class="lb-trans"><h2>非常規項目如何影響利潤？</h2>
</div><p>Importantly, our data indicates that Becton Dickinson's profit was reduced by US$1.3b, due to unusual items, over the last year. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's hardly a surprise given these line items are considered unusual. If Becton Dickinson doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.</p>
<div class="lb-trans"><p>重要的是，我們的數據表明，碧迪醫療的利潤因非常規項目在過去一年中減少了 13 億美元。看到非常規項目導致公司利潤下降並不理想，但從積極的一面看，情況可能會比預期更快改善。當我們分析全球絕大多數上市公司時，我們發現顯著的非常規項目通常不會重複。這並不令人驚訝，因為這些項目被視為非常規。如果碧迪醫療不再出現這些非常規費用，那麼在其他條件相同的情況下，我們預計其利潤在未來一年將會增加。</p>
</div><p>That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.</p>
<div class="lb-trans"><p>這可能會讓你想知道分析師對未來盈利能力的預測。幸運的是，你可以點擊這裏查看基於他們估計的未來盈利能力的互動圖表。</p>
</div><h2>Our Take On Becton Dickinson's Profit Performance</h2>
<div class="lb-trans"><h2>我們對碧迪醫療利潤表現的看法</h2>
</div><p>Unusual items (expenses) detracted from Becton Dickinson's earnings over the last year, but we might see an improvement next year. Based on this observation, we consider it likely that Becton Dickinson's statutory profit actually understates its earnings potential! And on top of that, its earnings per share have grown at 5.7% per year over the last three years. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you want to do dive deeper into Becton Dickinson, you'd also look into what risks it is currently facing. In terms of investment risks, <strong>we've identified 2 warning signs</strong> with Becton Dickinson, and understanding them should be part of your investment process.</p>
<div class="lb-trans"><p>非常規項目（費用）在過去一年中削弱了碧迪醫療的收益，但我們可能會在明年看到改善。基於這一觀察，我們認為碧迪醫療的法定利潤實際上低估了其盈利潛力！此外，其每股收益在過去三年中以每年 5.7% 的速度增長。當然，我們在分析其收益時僅僅是觸及了表面；還可以考慮利潤率、預測增長和投資回報等其他因素。如果你想更深入地瞭解碧迪醫療，你還需要關注它目前面臨的風險。在投資風險方面，<strong>我們已經識別出碧迪醫療的兩個警示信號</strong>，理解這些信號應該是你投資過程的一部分。</p>
</div><p>Today we've zoomed in on a single data point to better understand the nature of Becton Dickinson's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this <strong>free</strong> collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.</p>
<div class="lb-trans"><p>今天我們聚焦於一個單一的數據點，以更好地理解碧迪醫療的利潤性質。但如果你能夠專注於細節，總會有更多的發現。有些人認為高股本回報率是優質企業的良好標誌。雖然這可能需要你進行一些研究，但你可能會發現這份 <strong>免費</strong> 的高股本回報率公司集合，或者這份擁有顯著內部持股的股票名單對你有幫助。</p>
</div><h3>Valuation is complex, but we're here to simplify it.</h3>
<div class="lb-trans"><h3>估值是複雜的，但我們在這裏為你簡化。</h3>
</div><p>Discover if Becton Dickinson might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p>
<div class="lb-trans"><p>通過我們的詳細分析，發現碧迪醫療是否可能被低估或高估，分析內容包括 <strong>公允價值估計、潛在風險、股息、內部交易及其財務狀況。</strong></p>
</div><p>Access Free Analysis</p>
<div class="lb-trans"><p>獲取免費分析</p>
</div>

碧迪醫療（NYSE:BDX）的收益質量將令股東們感到滿意